openPR Logo
Press release

Increasing Prevalence Of HIV Is Expected To Drive Growth Of The HIV-Associated Lipodystrophy Treatment Market

02-06-2018 03:21 PM CET | Health & Medicine

Press release from: Pharmaceutical Report By CMI

Increasing Prevalence Of HIV Is Expected To Drive Growth Of

HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of lipodystrophy in people infected with HIV varies between 10% and 80%.
Increasing prevalence of HIV is expected to drive growth of the HIV-associated lipodystrophy treatment market
According to an article published in Journal of AIDS & Clinical Research in 2014, prevalence of lipodystrophy in patients suffering from HIV varies significantly and was estimated between 32.4% and 88.6%. According to World Health Organization (WHO) in 2017, more than 35 million people are suffering from HIV worldwide and an estimated 1.0 million people died from HIV in 2016. Increasing prevalence of HIV is expected to drive growth of the HIV-associated lipodystrophy market as most (32.4-88.6%) of the people suffering from HIV also suffer from HIV-associated lipodystrophy.
Approval of novel drugs in key regions such as North America is expected to drive the growth of HIV-Associated Lipodystrophy Market. For instance, in 2014, Theratechnologies Inc. received approval from Health Canada for its EGRIFTA. It is a growth hormone-releasing factor (GRF) for the treatment of HIV-associated lipodystrophy. EGRIFTA had also received the U.S. Food and Drug Administration (FDA) approval in 2010. Such approval of new drugs in the key region is expected to drive growth of the HIV-associated lipodystrophy treatment market.

Request For Sample Copy@
https://www.coherentmarketinsights.com/insight/request-sample/1269

North America is expected to hold a dominant position in HIV-related lipodystrophy treatment market, owing to favorable insurance policy. In 2016, The Massachusetts House and Senate approved a bill mandating insurance coverage to treat HIV drug side-effects such as HIV-related lipodystrophy. The approval of such insurance policy is expected to create a lucrative environment for HIV-related lipodystrophy market. Europe is expected to be the second largest market in HIV-related lipodystrophy market due to high prevalence of HIV in Europe. For instance, according to an article published in National Center for Biotechnology Information (NCBI) in 2014, approximately 860,000 adults were living with HIV in Europe and the highest prevalence of HIV were found in France (17.7 %), Spain (13.1 %), Greece (12.7 %) and Germany (11.5 %). 
According to The Joint United Nations Programme on HIV and AIDS (UNAIDS), about 36.7 million were living with HIV globally, and 30% of these people were unaware about their condition in 2016. Out of this 36.7 million people, 19.4 million were living in East and Southern Africa. The higher prevalence of HIV in region such as Africa which has limited access to drugs for disease such as HIV-associated lipodystrophy is expected to be major restraining factor in this market.
Major market players of HIV-associated lipodystrophy treatment market
Key players operating in global HIV-associated lipodystrophy treatment market include Theratechnologies Inc., GlaxoSmithKline plc, Novelion Therapeutics Inc., AstraZeneca plc, AbbVie Inc., and Bristol-Myers Squibb.

Get More Details On this Report:
https://www.coherentmarketinsights.com/ongoing-insight/hiv-associated-lipodystrophy-treatment-market-1269

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com
Visit our news Website: http://www.coherentchronicle.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Increasing Prevalence Of HIV Is Expected To Drive Growth Of The HIV-Associated Lipodystrophy Treatment Market here

News-ID: 933776 • Views: 448

More Releases from Pharmaceutical Report By CMI

Rising prevalence of diabetes is a major factor driving growth of the diabetic f …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the
Glucagon-Like Peptide-1 (Glp-1) Analogs Market Global Industry Insights, Trends, …
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic
Multiple Sclerosis Therapeutics Market to Surpass US$ 24.4 Billion by 2025
Increasing prevalence of multiple sclerosis to augment market growth Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. According to the Multiple Sclerosis Foundation, 2017, this autoimmune condition affects 2.5 million people with the global incidence of around 7 cases per 100,000 people per year. The study also states that prevalence rates varies between ethnic and geographical latitudes, ranging from 50 to
Diabetic Foot Ulcers Treatment Market to Surpass US$ 9.49 Billion Threshold by 2 …
Diabetic foot ulcers is a common condition in diabetic patients. It is a disabling disorder, which might lead to amputation of the leg. Mortality due to diabetic foot ulcers is high and chances of recurrence of cured foot ulcers is also high and this in turn leads to increasing demand for proper treatment of diabetic foot ulcers. Diabetic foot ulcer is caused due to neuropathic and vascular changes in the

All 5 Releases


More Releases for HIV

HIV-Associated Lipodystrophy Treatment Market - Increasing prevalence of HIV is …
HIV-associated lipodystrophy also known as lipodystrophy is a syndrome that occurs in HIV-infected patients. It is characterized by loss of subcutaneous fat from face, buttocks, arms and legs. Although the exact cause of HIV-associated lipodystrophy is not fully elucidated, some research evidence reported that it occurs in HIV-infected patients who are under antiretroviral medications. According to an article published in National Center for Biotechnology Information (NCBI) in 2014, prevalence of
Global HIV Drugs Market | Global HIV Drugs Industry | Global HIV Drugs Market Re …
Human immunodeficiency Virus (HIV) could be a chronic and severe sickness which might be transferred from one person to a different through blood-to-blood and sexual contact. it's a deadly disease that attacks immune cells called CD-4 cells, creating body vulnerable to infections and alternative diseases. Over the years, the rising prevalence of HIV sickness worldwide has completely influenced the demand for HIV medicine. HIV medicine facilitate in preventing the multiplication
HIV Therapeutics Market– South Africa's Aspen launches three-in-one HIV drug
Recent Developments Aspen Pharma care, a South Africa’s drug maker has launched a triple combination of tablet for the treatment of HIV in the country where the HIV virus is the most prevalent. The company's new Emdolten drug is a once a day tablet which is in the form of dolutegravir, an antiretroviral medication that balances the drug’s resistance. The company has launched Aspen Stavudine which was its first generic ARV
HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents Introduction to Human Immunodeficiency Virus (HIV) Vaccines 1.1 Overview 1.2 Antiquity of HIV Vaccine Need for the Development of HIV Vaccine Primer of HIV inside the Body 3.1 Inclusion of HIV Virus into the System 3.2 Interaction of HIV with Host 3.3 Eradication of HIV Virus HIV Vaccine Development Process 4.1 Introduction
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus. Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral